CN1615440A - 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法 - Google Patents

含有血管生成素－样蛋白质3angptl3的组合物及其使用方法 Download PDF

Info

Publication number
CN1615440A
CN1615440A CNA028271920A CN02827192A CN1615440A CN 1615440 A CN1615440 A CN 1615440A CN A028271920 A CNA028271920 A CN A028271920A CN 02827192 A CN02827192 A CN 02827192A CN 1615440 A CN1615440 A CN 1615440A
Authority
CN
China
Prior art keywords
angptl3
tissue
liver
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028271920A
Other languages
English (en)
Chinese (zh)
Inventor
纳波莱昂内·费拉拉
汉斯-彼得·格伯
乔·科沃尔斯基
玛丽亚·T·皮萨巴罗
丹尼尔·E·舍曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN1615440A publication Critical patent/CN1615440A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
CNA028271920A 2001-11-16 2002-11-13 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法 Pending CN1615440A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33242901P 2001-11-16 2001-11-16
US60/332,429 2001-11-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010102426068A Division CN101905024A (zh) 2001-11-16 2002-11-13 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN1615440A true CN1615440A (zh) 2005-05-11

Family

ID=23298191

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028271920A Pending CN1615440A (zh) 2001-11-16 2002-11-13 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法
CN2010102426068A Pending CN101905024A (zh) 2001-11-16 2002-11-13 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010102426068A Pending CN101905024A (zh) 2001-11-16 2002-11-13 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法

Country Status (14)

Country Link
US (3) US7267819B2 (enExample)
EP (1) EP1451578B1 (enExample)
JP (2) JP5105696B2 (enExample)
KR (2) KR20100029861A (enExample)
CN (2) CN1615440A (enExample)
AU (1) AU2002348286B2 (enExample)
CA (1) CA2464542C (enExample)
ES (1) ES2429034T3 (enExample)
IL (2) IL161542A0 (enExample)
MX (1) MXPA04004609A (enExample)
NO (1) NO336021B1 (enExample)
NZ (1) NZ532852A (enExample)
WO (1) WO2003044172A2 (enExample)
ZA (1) ZA200403070B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101852805A (zh) * 2009-03-31 2010-10-06 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
CN102625830A (zh) * 2009-07-14 2012-08-01 斯克里普斯研究所 间充质干细胞分化
CN101855241B (zh) * 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
CN105021827A (zh) * 2015-07-17 2015-11-04 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
CN110938144A (zh) * 2019-11-27 2020-03-31 上海市闵行区中心医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
CN111122872A (zh) * 2019-11-20 2020-05-08 中山大学附属第一医院 血管生成素样蛋白7在心力衰竭预后评估中的应用

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2429034T3 (es) 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas
AU2004266043B2 (en) * 2003-08-21 2007-09-20 Duchesnay Inc. Micronutrient supplement
CA2574791A1 (en) * 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US7807645B2 (en) 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
US8354111B2 (en) 2008-04-14 2013-01-15 Hadasit Medical Research Services And Development Ltd. Stable cell binding chimeric peptides
CN111700901A (zh) 2010-01-08 2020-09-25 Ionis制药公司 血管生成素样3表达的调节
AU2015200969A1 (en) * 2010-01-08 2015-03-19 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
EP2517028B1 (en) * 2010-02-02 2017-12-13 Arizona Board Of Regents Controlled tunnel gap device for sequencing polymers
EP2668499A4 (en) * 2011-01-29 2015-05-27 Astute Medical Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
JP6249447B2 (ja) 2012-01-24 2017-12-20 インターケー・ペプチド・セラピューティクス・リミテッド 癌治療用ペプチド剤
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
CN104062432B (zh) * 2013-03-22 2016-01-20 中山大学 ang2在制备ECTC血管类型肝癌诊断试剂及治疗药物中的应用
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
HUE052243T2 (hu) 2013-12-24 2021-04-28 Ionis Pharmaceuticals Inc Az angiopoietin-szerû 3 expressziójának modulációja
MX382230B (es) 2014-05-01 2025-03-13 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
EP3370708A4 (en) 2015-11-06 2019-06-26 Ionis Pharmaceuticals, Inc. MODULATION OF APOLIPOPROTEIN (A) EXPRESSION
EP3411392B1 (en) * 2016-02-04 2021-12-29 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
MX2018010401A (es) 2016-03-03 2019-03-06 Regeneron Pharma Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3.
PE20201287A1 (es) * 2017-09-14 2020-11-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020099482A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
US20240141029A1 (en) * 2021-03-05 2024-05-02 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
CN114934021B (zh) * 2022-04-21 2023-08-08 复旦大学附属儿科医院 一种Angptl3敲除的鼠永生化足细胞系及其应用
CN120254294B (zh) * 2025-06-05 2025-09-09 南昌大学第一附属医院 Angptl3在乙肝相关慢加急性肝衰竭预后中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
EP0917878A4 (en) 1997-02-26 2004-05-19 Toray Industries REMEDIES FOR HEPATITIS
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
JP2002533058A (ja) * 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９７個のヒト分泌タンパク質
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
KR100553300B1 (ko) 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
ES2429034T3 (es) 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101855241B (zh) * 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
CN101852805A (zh) * 2009-03-31 2010-10-06 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
WO2010111892A1 (zh) * 2009-03-31 2010-10-07 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
CN101852805B (zh) * 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
CN102625830A (zh) * 2009-07-14 2012-08-01 斯克里普斯研究所 间充质干细胞分化
CN102625830B (zh) * 2009-07-14 2016-03-02 斯克里普斯研究所 间充质干细胞分化
CN105601728A (zh) * 2009-07-14 2016-05-25 斯克里普斯研究所 间充质干细胞分化
CN105601728B (zh) * 2009-07-14 2020-01-10 斯克里普斯研究所 间充质干细胞分化
CN105021827A (zh) * 2015-07-17 2015-11-04 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
CN111122872A (zh) * 2019-11-20 2020-05-08 中山大学附属第一医院 血管生成素样蛋白7在心力衰竭预后评估中的应用
CN110938144A (zh) * 2019-11-27 2020-03-31 上海市闵行区中心医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途

Also Published As

Publication number Publication date
KR20100029861A (ko) 2010-03-17
CA2464542A1 (en) 2003-05-30
CN101905024A (zh) 2010-12-08
WO2003044172A3 (en) 2003-11-20
IL203894A (en) 2013-09-30
US20070134250A1 (en) 2007-06-14
EP1451578A4 (en) 2006-02-01
ES2429034T3 (es) 2013-11-12
JP2005521643A (ja) 2005-07-21
JP5105696B2 (ja) 2012-12-26
EP1451578A2 (en) 2004-09-01
JP2010100624A (ja) 2010-05-06
CA2464542C (en) 2015-01-20
IL161542A0 (en) 2004-09-27
WO2003044172B1 (en) 2004-03-18
NO20042410L (no) 2004-06-09
EP1451578B1 (en) 2013-08-21
US7267819B2 (en) 2007-09-11
US20030215451A1 (en) 2003-11-20
AU2002348286B2 (en) 2008-04-03
US20090098117A1 (en) 2009-04-16
NZ532852A (en) 2006-08-31
ZA200403070B (en) 2005-06-29
KR101012904B1 (ko) 2011-02-08
AU2002348286A1 (en) 2003-06-10
MXPA04004609A (es) 2004-08-12
WO2003044172A2 (en) 2003-05-30
KR20050044485A (ko) 2005-05-12
US8541376B2 (en) 2013-09-24
NO336021B1 (no) 2015-04-20

Similar Documents

Publication Publication Date Title
JP5105696B2 (ja) アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法
CN1146440C (zh) 血管内皮生长因子-b
CN1171997C (zh) 修饰的tie-2受体配体
CN1247780C (zh) 哺乳动物细胞因子样多肽－10
CN1552855A (zh) 人血管内皮生长因子2
CN1268744C (zh) 新的神经营养因子
CN1449445A (zh) Ev－vegf核酸和多肽及使用方法
CN101080419A (zh) 利用血管生成素样4蛋白的组合物和方法
CN1308451C (zh) 肿瘤坏死因子相关配基
CN1378595A (zh) 作为zalpha受体之配体的人细胞因子及其用途
CN101028523A (zh) 诊断和治疗肿瘤的方法及组合物
CN1402733A (zh) 血管生成蛋白及其应用
JP2012246296A (ja) 血管形成及び心血管疾患の調節に使用する肝細胞成長因子の新規インヒビター
CN1240834C (zh) Ly6h基因
CN1323716C (zh) Sarp－1在治疗和/或预防硬皮病中的应用
CN1292796A (zh) Meth1和meth2多核苷酸及多肽
HK1077877A (en) Composition comprising and method of using angiopoietin-like protein 3 angptl3
CN1961073A (zh) 切割型dance、dance复合体及其使用方法
CN1311818A (zh) 神经营养因子
CN101060855A (zh) 胃肠增殖因子及其用途
HK1008485B (en) Vascular endothelial growth factor-b
HK1075407A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
HK1065806A (en) Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
HK1076116A (en) Cystine-knot fold protein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077877

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050511

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077877

Country of ref document: HK